Cure­Vac’s lead mR­NA pro­gram flunks a crit­i­cal PhI­Ib study, rais­ing ques­tions for high-pro­file biotech uni­corns

Cure­Vac’s lead­ing mR­NA pro­gram CV9104, a prostate can­cer vac­cine, has failed a crit­i­cal Phase IIb study. And that sting­ing set­back for the most ad­vanced clin­i­cal study in the field will raise fresh ques­tions about a com­plex new tech­nol­o­gy that has at­tract­ed bil­lions of dol­lars in in­vest­ment cash.

The Ger­man biotech re­port­ed that not on­ly did CV9104 fail the pri­ma­ry end­point on im­prov­ing over­all sur­vival, there was al­so no im­prove­ment on pro­gres­sion-free sur­vival over a place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER